Zacks Investment Research lowered shares of Edap Tms (NASDAQ:EDAP) from a hold rating to a sell rating in a report issued on Monday, reports.

According to Zacks, “EDAP TMS S.A. develops, produces, markets and distributes minimally invasive medical devices, primarily for the treatment of urological diseases. They currently produce and market devices for treatment of benign prostate hyperplasia and urinary tract stones. They are also developing a third range of products for minimally invasive destruction of certain types of tumors. “

Several other research firms also recently issued reports on EDAP. TheStreet downgraded Timkensteel from a c- rating to a d+ rating in a report on Monday, June 17th. HC Wainwright set a $4.00 price objective on Uranium Energy and gave the stock a buy rating in a report on Tuesday, June 11th. Finally, ValuEngine upgraded YY from a sell rating to a hold rating in a report on Friday, June 7th.

Edap Tms stock opened at $2.71 on Monday. The business’s 50 day moving average is $2.82. The firm has a market cap of $81.19 million, a price-to-earnings ratio of 135.50 and a beta of 1.94. The company has a quick ratio of 1.97, a current ratio of 2.40 and a debt-to-equity ratio of 0.09. Edap Tms has a one year low of $1.35 and a one year high of $5.42.

Edap Tms (NASDAQ:EDAP) last released its quarterly earnings results on Wednesday, May 15th. The medical equipment provider reported $0.01 EPS for the quarter, hitting the consensus estimate of $0.01. The firm had revenue of $11.50 million for the quarter, compared to analyst estimates of $13.25 million. Edap Tms had a negative return on equity of 1.13% and a negative net margin of 0.36%. On average, sell-side analysts anticipate that Edap Tms will post 0.08 earnings per share for the current year.

A hedge fund recently raised its stake in Edap Tms stock. Fosun International Ltd boosted its holdings in shares of Edap Tms SA (NASDAQ:EDAP) by 45.9% during the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 363,485 shares of the medical equipment provider’s stock after purchasing an additional 114,342 shares during the quarter. Fosun International Ltd owned approximately 1.25% of Edap Tms worth $1,072,000 at the end of the most recent quarter. 10.31% of the stock is owned by institutional investors and hedge funds.

About Edap Tms

EDAP TMS SA, together with its subsidiaries, develops, produces, markets, distributes, and maintains a portfolio of minimally-invasive medical devices for the treatment of urological diseases worldwide. The company operates in two divisions: High Intensity Focused Ultrasound (HIFU), and Urology Devices and Services (UDS).

Read More: What is net income?

Get a free copy of the Zacks research report on Edap Tms (EDAP)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Edap Tms Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edap Tms and related companies with's FREE daily email newsletter.